We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience.
- Authors
Nakaya, Aya; Fujita, Shinya; Satake, Atsushi; Nakanishi, Takahisa; Azuma, Yoshiko; Tsubokura, Yukie; Hotta, Masaaki; Yoshimura, Hideaki; Ishii, Kazuyoshi; Ito, Tomoki; Nomura, Shosaku
- Abstract
Lenalidomide is an immunomodulatory drug administered orally in the treatment of multiple myeloma. Some elderly patients require a reduced lenalidomide dose because of comorbidities and/or adverse events. This study investigated the actual dose of lenalidomide in elderly patients, finding that most received reduced (5-10 mg) doses. The most common reasons for dose reduction were renal dysfunction (54% of patients), fatigue (grade = 3; 20%), hematologic disorder (grade = 3; 14%), and rash (grade = 3; 9%). Their median time to progression was 11.8 months and their median overall survival was 39.2 months. The overall response rate was 73%, including 17% with a complete response, 19% with a very good partial response, and 37% with a partial response. These results showed that, contrary to western countries, most patients were treated with a reduced dose of lenalidomide in Japan. However, it is suggested that continued treatment with a tolerable dose may yield favorable outcomes.
- Subjects
THALIDOMIDE; DRUG dosage; MULTIPLE myeloma treatment; MULTIPLE myeloma; DISEASES in older people; DRUG efficacy; DISEASE progression; PATIENTS
- Publication
Acta Haematologica, 2017, Vol 138, Issue 1, p55
- ISSN
0001-5792
- Publication type
Article
- DOI
10.1159/000477792